Screener
Recursion Pharmaceuticals, Inc. RXRX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (134,968) | (176,227) | (263,472) | (367,595) |
| Other income (loss), net | 3,962 | 4,330 | 10,359 | (6,947) |
| Loss before income tax benefit | (131,006) | (171,897) | (253,113) | (374,542) |
| Income tax benefit | 1 | — | 4,604 | 158 |
| Net loss | $(131,005) | $(171,897) | $(248,509) | $(374,384) |
| Per share data | ||||
| Net loss per share of Class A, B and Exchangeable common stock, basic and diluted | $(0.25) | $(0.41) | $(0.47) | $(0.91) |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted | 532,460,085 | 417,361,147 | 530,890,753 | 410,268,199 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s net income?
- Recursion Pharmaceuticals, Inc. (RXRX) reported net income of -$131.01M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s net income changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s net income increased by 23.8% year-over-year, from -$171.9M to -$131.01M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s net income?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s net income has grown at a 36.4% compound annual growth rate (CAGR), from -$186.48M to -$644.76M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Recursion Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude